Grifols, S.A. (BME:GRF)

Market Cap	6.46B
Revenue (ttm)	7.52B
Net Income (ttm)	372.72M
Shares Out	680.51M
EPS (ttm)	0.55
PE Ratio	19.49
Forward PE	11.55
Dividend	0.30 (2.81%)
Ex-Dividend Date	Aug 11, 2025

Volume	179,919
Average Volume	1,585,767
Open	10.70
Previous Close	10.66
Day's Range	10.65 - 10.77
52-Week Range	7.32 - 13.70
Beta	1.19
RSI	39.12
Earnings Date	Nov 4, 2025

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1909
• Employees: 23,833
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: GRF

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.